Literature DB >> 19264785

A yeast glycoprotein shows high-affinity binding to the broadly neutralizing human immunodeficiency virus antibody 2G12 and inhibits gp120 interactions with 2G12 and DC-SIGN.

Robert J Luallen1, Hu Fu, Caroline Agrawal-Gamse, Innocent Mboudjeka, Wei Huang, Fang-Hua Lee, Lai-Xi Wang, Robert W Doms, Yu Geng.   

Abstract

The human immunodeficiency virus type 1 (HIV-1) envelope (Env) protein contains numerous N-linked carbohydrates that shield conserved peptide epitopes and promote trans infection by dendritic cells via binding to cell surface lectins. The potent and broadly neutralizing monoclonal antibody 2G12 binds a cluster of high-mannose-type oligosaccharides on the gp120 subunit of Env, revealing a conserved and highly exposed epitope on the glycan shield. To find an effective antigen for eliciting 2G12-like antibodies, we searched for endogenous yeast proteins that could bind to 2G12 in a panel of Saccharomyces cerevisiae glycosylation knockouts and discovered one protein that bound weakly in a Delta pmr1 strain deficient in hyperglycosylation. 2G12 binding to this protein, identified as Pst1, was enhanced by adding the Delta mnn1 deletion to the Delta pmr1 background, ensuring the exposure of terminal alpha1,2-linked mannose residues on the D1 and D3 arms of high-mannose glycans. However, optimum 2G12 antigenicity was found when Pst1, a heavily N-glycosylated protein, was expressed with homogenous Man(8)GlcNAc(2) structures in Delta och1 Delta mnn1 Delta mnn4 yeast. Surface plasmon resonance analysis of this form of Pst1 showed high affinity for 2G12, which translated into Pst1 efficiently inhibiting gp120 interactions with 2G12 and DC-SIGN and blocking 2G12-mediated neutralization of HIV-1 pseudoviruses. The high affinity of the yeast glycoprotein Pst1 for 2G12 highlights its potential as a novel antigen to induce 2G12-like antibodies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19264785      PMCID: PMC2682088          DOI: 10.1128/JVI.02537-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  49 in total

1.  HIV vaccine design and the neutralizing antibody problem.

Authors:  Dennis R Burton; Ronald C Desrosiers; Robert W Doms; Wayne C Koff; Peter D Kwong; John P Moore; Gary J Nabel; Joseph Sodroski; Ian A Wilson; Richard T Wyatt
Journal:  Nat Immunol       Date:  2004-03       Impact factor: 25.606

2.  Isolation, characterization, and properties of Saccharomyces cerevisiae mnn mutants with nonconditional protein glycosylation defects.

Authors:  C E Ballou
Journal:  Methods Enzymol       Date:  1990       Impact factor: 1.600

3.  Carbohydrate structures of the human-immunodeficiency-virus (HIV) recombinant envelope glycoprotein gp120 produced in Chinese-hamster ovary cells.

Authors:  T Mizuochi; M W Spellman; M Larkin; J Solomon; L J Basa; T Feizi
Journal:  Biochem J       Date:  1988-09-01       Impact factor: 3.857

4.  Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells.

Authors:  C K Leonard; M W Spellman; L Riddle; R J Harris; J N Thomas; T J Gregory
Journal:  J Biol Chem       Date:  1990-06-25       Impact factor: 5.157

5.  DC-SIGN binds to HIV-1 glycoprotein 120 in a distinct but overlapping fashion compared with ICAM-2 and ICAM-3.

Authors:  Stephen V Su; Patrick Hong; Sarah Baik; Oscar A Negrete; Kevin B Gurney; Benhur Lee
Journal:  J Biol Chem       Date:  2004-02-16       Impact factor: 5.157

6.  Binding of high-mannose-type oligosaccharides and synthetic oligomannose clusters to human antibody 2G12: implications for HIV-1 vaccine design.

Authors:  Lai-Xi Wang; Jiahong Ni; Suddham Singh; Hengguang Li
Journal:  Chem Biol       Date:  2004-01

7.  Design and synthesis of a template-assembled oligomannose cluster as an epitope mimic for human HIV-neutralizing antibody 2G12.

Authors:  Hengguang Li; Lai-Xi Wang
Journal:  Org Biomol Chem       Date:  2004-01-22       Impact factor: 3.876

8.  Purification of an acidic alpha-D-mannosidase from Aspergillus saitoi and specific cleavage of 1,2-alpha-D-mannosidic linkage in yeast mannan.

Authors:  E Ichishima; M Arai; Y Shigematsu; H Kumagai; R Sumida-Tanaka
Journal:  Biochim Biophys Acta       Date:  1981-03-13

9.  The yeast secretory pathway is perturbed by mutations in PMR1, a member of a Ca2+ ATPase family.

Authors:  H K Rudolph; A Antebi; G R Fink; C M Buckley; T E Dorman; J LeVitre; L S Davidow; J I Mao; D T Moir
Journal:  Cell       Date:  1989-07-14       Impact factor: 41.582

10.  A human serum mannose-binding protein inhibits in vitro infection by the human immunodeficiency virus.

Authors:  R A Ezekowitz; M Kuhlman; J E Groopman; R A Byrn
Journal:  J Exp Med       Date:  1989-01-01       Impact factor: 14.307

View more
  23 in total

1.  Antibody 2G12 recognizes di-mannose equivalently in domain- and nondomain-exchanged forms but only binds the HIV-1 glycan shield if domain exchanged.

Authors:  Katie J Doores; Zara Fulton; Michael Huber; Ian A Wilson; Dennis R Burton
Journal:  J Virol       Date:  2010-08-11       Impact factor: 5.103

2.  Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens.

Authors:  Katie J Doores; Camille Bonomelli; David J Harvey; Snezana Vasiljevic; Raymond A Dwek; Dennis R Burton; Max Crispin; Christopher N Scanlan
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-19       Impact factor: 11.205

3.  Antibodies elicited by yeast glycoproteins recognize HIV-1 virions and potently neutralize virions with high mannose N-glycans.

Authors:  Hong Zhang; Hu Fu; Robert J Luallen; Bingfen Liu; Fang-Hua Lee; Robert W Doms; Yu Geng
Journal:  Vaccine       Date:  2015-08-13       Impact factor: 3.641

Review 4.  Rational antibody-based HIV-1 vaccine design: current approaches and future directions.

Authors:  Laura M Walker; Dennis R Burton
Journal:  Curr Opin Immunol       Date:  2010-03-17       Impact factor: 7.486

5.  Preparation, characterization and immunogenicity of HIV-1 related high-mannose oligosaccharides-CRM197 glycoconjugates.

Authors:  Anna Kabanova; Roberto Adamo; Daniela Proietti; Francesco Berti; Marta Tontini; Rino Rappuoli; Paolo Costantino
Journal:  Glycoconj J       Date:  2010-06-04       Impact factor: 2.916

Review 6.  Analysis of carbohydrates and glycoconjugates by matrix-assisted laser desorption/ionization mass spectrometry: an update for 2009-2010.

Authors:  David J Harvey
Journal:  Mass Spectrom Rev       Date:  2014-05-26       Impact factor: 10.946

7.  In-solution virus capture assay helps deconstruct heterogeneous antibody recognition of human immunodeficiency virus type 1.

Authors:  Daniel P Leaman; Heather Kinkead; Michael B Zwick
Journal:  J Virol       Date:  2010-01-20       Impact factor: 5.103

8.  A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals.

Authors:  Laura M Walker; Melissa D Simek; Frances Priddy; Johannes S Gach; Denise Wagner; Michael B Zwick; Sanjay K Phogat; Pascal Poignard; Dennis R Burton
Journal:  PLoS Pathog       Date:  2010-08-05       Impact factor: 6.823

Review 9.  Structural insights into key sites of vulnerability on HIV-1 Env and influenza HA.

Authors:  Jean-Philippe Julien; Peter S Lee; Ian A Wilson
Journal:  Immunol Rev       Date:  2012-11       Impact factor: 12.988

10.  Antibodies against Manalpha1,2-Manalpha1,2-Man oligosaccharide structures recognize envelope glycoproteins from HIV-1 and SIV strains.

Authors:  Robert J Luallen; Caroline Agrawal-Gamse; Hu Fu; David F Smith; Robert W Doms; Yu Geng
Journal:  Glycobiology       Date:  2009-11-17       Impact factor: 4.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.